Scholarlink

<p>Graft-<i>versus</i>-host disease (GVHD) remains one of the most severe complications following allogeneic hematopoietic stem cell transplantation (HSCT), significantly contributing to transplant-related morbidity and mortality. While systemic corticosteroids are the standard first-line therapy, a substantial proportion of patients develop steroid-refractory GVHD, which is associated with poor clinical outcomes. Mesenchymal stromal cells (MSCs), a heterogeneous population of multipotent stromal cells derived from diverse tissue sources, have garnered increasing attention due to their immunomodulatory capacity and ability to promote tissue repair. Preclinical studies and early-phase clinical trials have demonstrated the potential of MSCs to enhance hematopoietic engraftment, reduce the incidence and severity of GVHD, and improve immune homeostasis. Encouraging data, particularly in the treatment of steroid-resistant acute GVHD, suggest a favorable safety profile and therapeutic efficacy. In this review, we comprehensively summarize the current understanding of MSCs biology, preclinical evidence, and clinical applications in the context of GVHD, and we further discuss emerging strategies for optimizing MSC-based therapies to enhance their clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal Stromal Cells and Graft-versus-Host Disease: Preclinical and Clinical Studies

  • 期刊论文

  • 发表日期：

    2025年6月14日

查看全文
  • Rui Wang,
  • Jingkang Xiong,
  • Qing Xu,
  • Ya Zhou,
  • Shijie Yang,
  • Qingxiao Song,
  • Xiaoqi Wang,
  • Xi Zhang

摘要

Graft-versus-host disease (GVHD) remains one of the most severe complications following allogeneic hematopoietic stem cell transplantation (HSCT), significantly contributing to transplant-related morbidity and mortality. While systemic corticosteroids are the standard first-line therapy, a substantial proportion of patients develop steroid-refractory GVHD, which is associated with poor clinical outcomes. Mesenchymal stromal cells (MSCs), a heterogeneous population of multipotent stromal cells derived from diverse tissue sources, have garnered increasing attention due to their immunomodulatory capacity and ability to promote tissue repair. Preclinical studies and early-phase clinical trials have demonstrated the potential of MSCs to enhance hematopoietic engraftment, reduce the incidence and severity of GVHD, and improve immune homeostasis. Encouraging data, particularly in the treatment of steroid-resistant acute GVHD, suggest a favorable safety profile and therapeutic efficacy. In this review, we comprehensively summarize the current understanding of MSCs biology, preclinical evidence, and clinical applications in the context of GVHD, and we further discuss emerging strategies for optimizing MSC-based therapies to enhance their clinical utility.